Biosino Bio-Technology and Science Incorporation submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing on 03 August 2026, covering the period ended 31 July 2026. Key details are as follows:

1. Share-capital stability • Authorised / registered share capital remained unchanged at RMB 144.71 million, split between 64.29 million H shares and 80.42 million domestic shares, each with a par value of RMB 1. • Issued share capital also held steady at 144.71 million shares, mirroring the authorised balance. No shares were issued, cancelled or repurchased during the month. • The company reported zero treasury shares at both the beginning and end of the period.

2. Public-float compliance The 64.29 million H shares listed in Hong Kong continue to satisfy the Exchange’s minimum 25 % public-float requirement, as confirmed by the issuer.

3. Absence of dilutive instruments No movements were recorded in share options, warrants, convertible securities or other equity-linked instruments.

4. Corporate snapshot • Filing date: 03 August 2026 • Reporting period: Month ended 31 July 2026 • Responsible officer: Company Secretary Tung Woon Cheung, Eric

With no equity movements and full compliance with listing rules, Biosino Bio-Technology maintains a stable capital structure heading into the next reporting period.